Cryofocus Medtech (Shanghai) Co., Ltd.'s (HKG:6922) Market Cap Surged HK$471m Last Week, Private Companies Who Have a Lot Riding on the Company Were Rewarded
Cryofocus Medtech (Shanghai) Co., Ltd.'s (HKG:6922) Market Cap Surged HK$471m Last Week, Private Companies Who Have a Lot Riding on the Company Were Rewarded
Key Insights
關鍵見解
- The considerable ownership by private companies in Cryofocus Medtech (Shanghai) indicates that they collectively have a greater say in management and business strategy
- The top 3 shareholders own 52% of the company
- 16% of Cryofocus Medtech (Shanghai) is held by insiders
- 私營公司在Cryofocus Medtech(上海)擁有大量所有權,這表明它們在管理和業務戰略方面集體擁有更大的發言權
- 前三名股東擁有公司52%的股份
- Cryofocus Medtech(上海)16%的股份由內部人士持有
A look at the shareholders of Cryofocus Medtech (Shanghai) Co., Ltd. (HKG:6922) can tell us which group is most powerful. The group holding the most number of shares in the company, around 35% to be precise, is private companies. That is, the group stands to benefit the most if the stock rises (or lose the most if there is a downturn).
看看Cryofocus醫療科技(上海)有限公司(HKG: 6922)的股東可以告訴我們哪個集團最強大。持有該公司股份最多的集團是私營公司,準確地說約爲35%。也就是說,如果股票上漲,該集團將受益最大(如果股價下跌,則損失最大)。
Clearly, private companies benefitted the most after the company's market cap rose by HK$471m last week.
顯然,在上週該公司的市值上漲了4.71億港元之後,私營公司受益最大。
In the chart below, we zoom in on the different ownership groups of Cryofocus Medtech (Shanghai).
在下圖中,我們放大了Cryofocus Medtech(上海)的不同所有權組。
![ownership-breakdown](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240409/0-94f389c2b3f84aa5f7803c23bc1a5480-0-cce10e692fcdded4476588b8ccd708b7.png/big)
What Does The Institutional Ownership Tell Us About Cryofocus Medtech (Shanghai)?
關於Cryofocus Medtech(上海),機構所有權告訴我們什麼?
Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices.
許多機構根據近似於當地市場的指數來衡量自己的表現。因此,他們通常會更多地關注主要指數中包含的公司。
Cryofocus Medtech (Shanghai) already has institutions on the share registry. Indeed, they own a respectable stake in the company. This suggests some credibility amongst professional investors. But we can't rely on that fact alone since institutions make bad investments sometimes, just like everyone does. When multiple institutions own a stock, there's always a risk that they are in a 'crowded trade'. When such a trade goes wrong, multiple parties may compete to sell stock fast. This risk is higher in a company without a history of growth. You can see Cryofocus Medtech (Shanghai)'s historic earnings and revenue below, but keep in mind there's always more to the story.
Cryofocus Medtech(上海)已經在股份登記處設立了機構。事實上,他們擁有該公司可觀的股份。這表明專業投資者有一定的信譽。但是我們不能僅僅依靠這個事實,因爲機構有時會像所有人一樣進行不良投資。當多家機構擁有一隻股票時,總是存在處於 “擁擠交易” 的風險。當這樣的交易出錯時,多方可能會競相快速出售股票。對於沒有增長曆史的公司,這種風險更高。您可以在下面看到Cryofocus Medtech(上海)的歷史收益和收入,但請記住,故事總是有更多內容。
![earnings-and-revenue-growth](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240409/0-94f389c2b3f84aa5f7803c23bc1a5480-1-127feb166992f3a9c1c19e8670cd8a6e.png/big)
We note that hedge funds don't have a meaningful investment in Cryofocus Medtech (Shanghai). The company's largest shareholder is Ningbo Linfeng Biotechnology Co., Ltd, with ownership of 33%. For context, the second largest shareholder holds about 11% of the shares outstanding, followed by an ownership of 9.1% by the third-largest shareholder. Shiwen Lv, who is the third-largest shareholder, also happens to hold the title of Member of the Board of Directors. Additionally, the company's CEO Jun Zhu directly holds 0.6% of the total shares outstanding.
我們注意到,對沖基金沒有對Cryofocus Medtech(上海)進行有意義的投資。公司的最大股東是寧波林峯生物技術有限公司,持股33%。就背景而言,第二大股東持有約11%的已發行股份,其次是第三大股東持有9.1%的所有權。第三大股東呂世文也恰好擁有董事會成員的頭銜。此外,該公司首席執行官朱軍直接持有已發行股份總額的0.6%。
To make our study more interesting, we found that the top 3 shareholders have a majority ownership in the company, meaning that they are powerful enough to influence the decisions of the company.
爲了使我們的研究更有趣,我們發現前三名股東擁有公司的多數股權,這意味着他們足夠強大,足以影響公司的決策。
While it makes sense to study institutional ownership data for a company, it also makes sense to study analyst sentiments to know which way the wind is blowing. There is a little analyst coverage of the stock, but not much. So there is room for it to gain more coverage.
雖然研究公司的機構所有權數據是有意義的,但研究分析師的情緒以了解風向哪個方向吹來也是有意義的。分析師對該股的報道很少,但報道不多。因此,它還有獲得更多報道的餘地。
Insider Ownership Of Cryofocus Medtech (Shanghai)
Cryofocus Medtech(上海)的內部所有權
While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. Management ultimately answers to the board. However, it is not uncommon for managers to be executive board members, especially if they are a founder or the CEO.
儘管內部人士的確切定義可能是主觀的,但幾乎每個人都認爲董事會成員是內部人士。管理層最終對董事會負責。但是,經理成爲執行委員會成員的情況並不少見,尤其是當他們是創始人或首席執行官時。
I generally consider insider ownership to be a good thing. However, on some occasions it makes it more difficult for other shareholders to hold the board accountable for decisions.
我通常認爲內部所有權是一件好事。但是,在某些情況下,這使其他股東更難追究董事會對決策的責任。
Our information suggests that insiders maintain a significant holding in Cryofocus Medtech (Shanghai) Co., Ltd.. It has a market capitalization of just HK$2.7b, and insiders have HK$449m worth of shares in their own names. We would say this shows alignment with shareholders, but it is worth noting that the company is still quite small; some insiders may have founded the business. You can click here to see if those insiders have been buying or selling.
我們的信息表明,內部人士持有Cryofocus醫療科技(上海)有限公司的大量股份。它的市值僅爲27億港元,內部人士以自己的名義持有價值4.49億港元的股票。我們可以說這表明了與股東的一致性,但值得注意的是,該公司仍然很小;一些內部人士可能已經創立了該公司。你可以點擊這裏查看這些內部人士是否在買入或賣出。
General Public Ownership
一般公有制
The general public-- including retail investors -- own 16% stake in the company, and hence can't easily be ignored. While this group can't necessarily call the shots, it can certainly have a real influence on how the company is run.
包括散戶投資者在內的公衆擁有該公司16%的股份,因此不容忽視。雖然這個團體不一定能做主,但它肯定會對公司的運營方式產生真正的影響。
Private Equity Ownership
私募股權所有權
With a stake of 13%, private equity firms could influence the Cryofocus Medtech (Shanghai) board. Some might like this, because private equity are sometimes activists who hold management accountable. But other times, private equity is selling out, having taking the company public.
私募股權公司持有13%的股份,可能會影響Cryofocus Medtech(上海)董事會。有些人可能會喜歡這樣,因爲私募股權有時是追究管理層責任的激進分子。但是其他時候,私募股權在公司上市後正在售罄。
Private Company Ownership
私人公司所有權
We can see that Private Companies own 35%, of the shares on issue. Private companies may be related parties. Sometimes insiders have an interest in a public company through a holding in a private company, rather than in their own capacity as an individual. While it's hard to draw any broad stroke conclusions, it is worth noting as an area for further research.
我們可以看到,私人公司擁有已發行股份的35%。私人公司可能是關聯方。有時,內部人士通過控股私營公司而不是以個人身份對上市公司感興趣。雖然很難得出任何廣泛的中風結論,但值得注意的是,這是一個需要進一步研究的領域。
Next Steps:
後續步驟:
While it is well worth considering the different groups that own a company, there are other factors that are even more important. To that end, you should be aware of the 1 warning sign we've spotted with Cryofocus Medtech (Shanghai) .
儘管值得考慮擁有公司的不同群體,但還有其他因素更爲重要。爲此,你應該注意我們在Cryofocus Medtech(上海)發現的1個警告信號。
If you are like me, you may want to think about whether this company will grow or shrink. Luckily, you can check this free report showing analyst forecasts for its future.
如果你像我一樣,你可能需要考慮這家公司是會成長還是會萎縮。幸運的是,您可以查看這份免費報告,其中顯示了分析師對其未來的預測。
NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.
注意:本文中的數字是使用過去十二個月的數據計算得出的,這些數據是指截至財務報表日期當月最後一天的12個月期間。這可能與全年年度報告數據不一致。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。